CARsgen Therapeutics Holdings Ltd
HKEX:2171
Intrinsic Value
CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd's market capitalization is 3.1B HKD.
CARsgen Therapeutics Holdings Ltd stock price is 5.33 HKD.
CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. Open DCF Valuation
CARsgen Therapeutics Holdings Ltd. Open Relative Valuation
CARsgen Therapeutics Holdings Ltd has upside potential of 174% compared to the average analyst price target.
Open Wall St Estimates
CARsgen Therapeutics Holdings Ltd has negative Operating Income for the last twelve months.
CARsgen Therapeutics Holdings Ltd has negative Net Income for the last twelve months.
CARsgen Therapeutics Holdings Ltd's ROE (Return on Equity) for the past 12 months is negative and is equal to -35%.
CARsgen Therapeutics Holdings Ltd's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -170%.
CARsgen Therapeutics Holdings Ltd has negative Free Cash Flow for the last twelve months.
CARsgen Therapeutics Holdings Ltd's D/E (Debt to Equity) is very low and is equal to 0.04.
CARsgen Therapeutics Holdings Ltd has negative three-year average ROE (Return on Equity): -57%. The company is not efficient at transforming stockholders' equity into net income.
CARsgen Therapeutics Holdings Ltd has negative three-year average ROIC (Return on Invested Capital): -155%. The company is not efficient at using invested capital to generate operating income.
CARsgen Therapeutics Holdings Ltd's short-term assets (2B CNY) exceed its short-term liabilties (196m CNY).
CARsgen Therapeutics Holdings Ltd's long-term assets (2B CNY) exceed its long-term liabilties (456m CNY).
CARsgen Therapeutics Holdings Ltd has negative Net Debt. This means that the company has more cash and short-term investments (2B CNY) than debt (70m CNY).
CARsgen Therapeutics Holdings Ltd's Altman Z-Score is very high and is equal to 4.83.
CARsgen Therapeutics Holdings Ltd doesn't generate enough operating income (-768m CNY) to safely cover interest payments on its debt (9m CNY).
Fundamental Analysis
CARsgen Therapeutics Holdings Ltd
Balance Sheet Decomposition
CARsgen Therapeutics Holdings Ltd
| Current Assets | 1.9B |
| Cash & Short-Term Investments | 1.8B |
| Receivables | 9.8m |
| Other Current Assets | 13.5m |
| Non-Current Assets | 384.1m |
| PP&E | 361.4m |
| Intangibles | 8.7m |
| Other Non-Current Assets | 14.1m |
| Current Liabilities | 196.2m |
| Accrued Liabilities | 158m |
| Other Current Liabilities | 38.2m |
| Non-Current Liabilities | 259.3m |
| Long-Term Debt | 70.5m |
| Other Non-Current Liabilities | 188.8m |
Earnings Waterfall
CARsgen Therapeutics Holdings Ltd
|
Revenue
|
0
CNY
|
|
Operating Expenses
|
-767.6m
CNY
|
|
Operating Income
|
-767.6m
CNY
|
|
Other Expenses
|
19.9m
CNY
|
|
Net Income
|
-747.8m
CNY
|
Free Cash Flow Analysis
CARsgen Therapeutics Holdings Ltd
Profitability Score
Profitability Due Diligence
CARsgen Therapeutics Holdings Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
CARsgen Therapeutics Holdings Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
CARsgen Therapeutics Holdings Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
CARsgen Therapeutics Holdings Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
CARsgen Therapeutics Holdings Ltd
According to Wall Street analysts, the average 1-year price target for
CARsgen Therapeutics Holdings Ltd
is 14.6 HKD
with a low forecast of 8.7 HKD and a high forecast of 21.02 HKD.
Shareholder Return
Price
CARsgen Therapeutics Holdings Ltd
| Average Annual Return | -25.82% |
| Standard Deviation of Annual Returns | 14.35% |
| Max Drawdown | -93% |
| Market Capitalization | 3.1B HKD |
| Shares Outstanding | 575 644 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
CARsgen Therapeutics Holdings Ltd
Country
Industry
Market Cap
Dividend Yield
Description
CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.
You don't have any saved screeners yet
